Apr 21, 2020 · Adding Nanna’s proprietary and advanced screening platform with new DNA-encoded chemical libraries (DELs) technology significantly bolsters Astellas’ early stage drug development capabilities. Nanna’s unique capabilities enable the creation and rapid testing of more diverse chemical libraries.

Apr 24, 2020 · Astellas Pharma paid roughly $15 million to acquire UK-based Nanna Therapeutics, which is developing therapies that modulate function of the cell’s power source, mitochondria.

Apr 28, 2020 · Japanese pharma giant Astellas has acquired the UK biotech Nanna Therapeutics for up to €80M (£69.5M) in a deal to boost the development of drugs for unspecified age-related conditions and mitochondrial diseases.

Adding Nanna’s proprietary and advanced screening platform with new DNA-encoded chemical libraries (DELs) technology significantly bolsters Astellas’ early stage drug development capabilities.

Tokyo, Cambridge: Astellas Pharma Inc. and Nanna Therapeutics Limited have announced that Astellas has acquired Nanna, a biotech company headquartered in the United Kingdom, that is focused on addressing age-related diseases with high unmet medical need including mitochondria-related diseases.

Adding Nanna’s proprietary and advanced screening platform with new DNA-encoded chemical libraries (DELs) technology significantly bolsters Astellas’ early stage drug development capabilities. Nanna’s unique capabilities enable the creation and rapid testing of more diverse chemical libraries.

– Nanna’s unique screening platform has great potential to create novel programs, leading to maximization of mitochondria-related research TOKYO and CAMBRIDGE (UK), April 21, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Nanna Therapeutics Limited (CEO: David Williams, Ph.D., “Nanna”) today announced that Astellas has acquired ...

Astellas, via its subsidiary in the United Kingdom, Astellas Pharma Europe Ltd., has bought all of the issued share capital of Nanna via execution of a Share Purchase Agreement.

“We believe this acquisition will enable us to create new solutions that address unmet medical needs by combining Nanna’s unique technology platform with our research and development capabilities related to mitochondrial diseases,” said Kenji …

Apr 24, 2020 · Tokyo-based multinational pharma company Astellas announced earlier this week that it had acquired U.K.-based biotech company Nanna Therapeutics, through a share purchase agreement executed by its UK subsidiary, Astellas Pharma Europe Ltd.